Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec 2;71(23):1883-8.
doi: 10.1212/01.wnl.0000336652.05779.ea.

How redesigning AD clinical trials might increase study partners' willingness to participate

Jason Karlawish  1 , Mark S Cary, Jonathan Rubright, Tom Tenhave
Affiliations

How redesigning AD clinical trials might increase study partners' willingness to participate

Jason Karlawish et al. Neurology. .

Abstract

Background: Timely recruiting and retaining participants into Alzheimer disease (AD) clinical trials is a challenge. We used conjoint analysis to identify how alterations in attributes of clinical trial design improve willingness to participate: risk, home visits, car service, or increased chance of receiving intervention.

Method: A total of 108 study partners of patients with very mild to severe stage AD rated willingness to allow their relative to participate in eight clinical trials that varied combinations of the four attributes.

Results: The highest utility was for home visits (0.89) which essentially compensated for the disutility of high risk (-0.85). The combination of home visits and car service was redundant, with almost no increase in utility over home visits alone. Seventeen percent were willing to participate in a trial with no amenities; the addition of home visits increased predicted willingness to participate to 27%; low risk, home visits, and higher chance of active treatment increased predicted willingness to 60%. The value of reducing the hassles of travel correlated well with measures of AD severity (activities of daily living r = 0.41, p < 0.001; basic activities of daily living r = 0.38, p < 0.001; Neuropsychiatric Inventory severity p = 0.24, p = 0.01; Neuropsychiatric Inventory distress r = 0.23, p < 0.02). No association was found between degree of study partner burden and willingness to tolerate risk of an intervention.

Conclusion: Clinical trials that reduce travel inconvenience may offset the disincentive of study features such as the risk of intervention and may also increase willingness to participate. Redesigning trials may also help recruit patients with more severe Alzheimer disease. Shorter recruitment periods and increased retention rates may offset costs of these changes.

PubMed Disclaimer

Figures

None
Figure Factor utilities A positive value means the factor is associated with increased willingness to participate and a negative value means the factor is associated with a decreased willingness to participate.
See this image and copyright information in PMC

References

    1. Alzheimer’s Association. What is Alzheimer’s? Available at: http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed March 7, 2008.
    1. Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR. What patients say about medical research. IRB: A Review of Human Subjects Research 1998;20:1–7. - PubMed
    1. Karlawish JHT, Casarett D, Klocinksi J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? Neurology 2001;56:789–792. - PubMed
    1. Louviere JJ. Analyzing Decision Making: Metric Conjoint Analysis. Newbury Park, CA: Sage Publications, 1988.
    1. Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54:3–19.

Publication types

MeSH terms